IP Library Granted Patent US 10,633,439
Granted Patent B2
US 10,633,439 · App. 16/286,231 · Granted Apr 28, 2020

Antibodies for IL-17C

Inventors: Jan Dominik Haas (München, DE); Jürgen Klattig (Peißenberg, DE); Nick Ernest Rene Vandeghinste (Mechelen, BE)
Assignees: MORPHOSYS AG; GALAPAGOS NV
C07K16/244C12N15/62C12N15/63A61K39/395A61K2039/505A61K2039/54A61K2039/545C07K2317/21C07K2317/24C07K2317/33C07K2317/55C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,633,439
App. No.
16/286,231
Granted
Apr 28, 2020
Kind
B2
Abstract

The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.

Claims (32)

1. A nucleic acid encoding an isolated antibody or antibody fragment specific for IL-17C, wherein said antibody or antibody fragment comprises

(a) a heavy chain complementarity determining region (HCDR)1 comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 9, a light chain complementarity determining region (LCDR)1 region comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 15, or

(b) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 28.

2. A vector comprising the nucleic acid according to claim 1 .

3. A host cell comprising the vector according to claim 2 .

4. The nucleic acid according to claim 1 , wherein said encoded antibody or antibody fragment comprises:

a) a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO:17 and a light chain variable region (V L ) comprising the amino acid sequence of SEQ ID NO:16; or

b) a V H comprising the amino acid sequence of SEQ ID NO:30 and a V L comprising the amino acid sequence of SEQ ID NO:29.

5. A vector comprising the nucleic acid according to claim 4 .

6. A host cell comprising the vector according to claim 5 .

7. The nucleic acid according to claim 4 , wherein said encoded antibody or antibody fragment comprises:

a) a heavy chain comprising the amino acid sequence of SEQ ID NO:43 and a light chain comprising the amino acid sequence of SEQ ID NO:42; or

b) a heavy chain comprising the amino acid sequence of SEQ ID NO:56 and a light chain comprising the amino acid sequence of SEQ ID NO:55.

8. A vector comprising the nucleic acid according to claim 7 .

9. A host cell comprising the vector according to claim 8 .

10. A nucleic acid encoding:

i) an antibody V H comprising a heavy chain complementarity determining region (HCDR)1 comprising the amino acid sequence of SEQ ID NO:7, a HCDR2 region comprising the amino acid sequence of SEQ ID NO:8, a HCDR3 region comprising the amino acid sequence of SEQ ID NO:9;

ii) an antibody V L comprising a light chain complementarity determining region (LCDR)1 region comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID NO:14 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO:15;

iii) an antibody V H comprising a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 22; or

iv) an antibody V L comprising a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 28.

11. A vector comprising at least one nucleic acid according to claim 10 .

12. A host cell comprising at least one vector according to claim 11 .

13. A nucleic acid encoding:

i) an antibody V H comprising the amino acid sequence of SEQ ID NO:17;

ii) an antibody V L comprising the amino acid sequence of SEQ ID NO:16;

iii) an antibody V H comprising the amino acid sequence of SEQ ID NO:30; or

iv) an antibody V L comprising the amino acid sequence of SEQ ID NO:29.

14. A vector comprising at least one nucleic acid according to claim 13 .

15. A host cell comprising at least one vector according to claim 14 .

16. The nucleic acid according to claim 13 , comprising the nucleic acid sequence set forth as SEQ ID NO:18-19, SEQ ID NO:44-45, SEQ ID NO:67-70, SEQ ID NO:31-32, SEQ ID NO:57, or SEQ ID NO:71.

17. A vector comprising at least one nucleic acid according to claim 16 .

18. A host cell comprising at least one vector according to claim 17 .

Assignments (3)
CHANGE OF NAME Recorded May 1, 2025
From: MORPHOSYS AG
To: MORPHOSYS GMBH
Reel/Frame 071149/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: HAAS, JAN DOMINIK; KLATTIG, JUERGEN
To: MORPHOSYS AG.
Reel/Frame 052068/0532 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: VANDEGHINSTE, NICK ERNEST RENE
To: GALAPAGOS NV
Reel/Frame 052068/0653 →
Priority Claims (2)
EP 16156582 · Feb 19, 2016 · regional
EP 16156651 · Feb 22, 2016 · regional
Continuity (3)
Continuation 16058143 · Aug 8, 2018
Continuation PCTEP2017053592 · Feb 17, 2017
Related Publication 20190202906A1 · Jul 4, 2019